COVID-19 Causes Decreased Testosterone Levels, Not Increased Levels
COVID-19 infection is associated with significantly reduced testosterone levels in men, not elevated levels, and this represents a hormonal imbalance that correlates with disease severity. The evidence consistently demonstrates that lower testosterone predicts worse outcomes, including ICU admission and mortality 1, 2, 3, 4.
Direction of Testosterone Change
The hormonal imbalance caused by COVID-19 manifests as:
- Decreased total testosterone levels during acute infection, with severity-dependent reductions 2, 3
- Secondary hypogonadism (low testosterone with low/normal LH and FSH) in approximately 85-90% of hospitalized men 3, 1
- Transient suppression that typically recovers within 3-6 months after infection 5
In one study examining men with pre-COVID testosterone measurements, levels dropped from 458 ± 198 ng/dL pre-infection to 315 ± 120 ng/dL during acute COVID-19 (p = 0.003) 2. This represents a substantial decline, not an increase.
Mechanism of Hormonal Imbalance
The testosterone reduction occurs through multiple pathways 1:
- Cytokine-driven gonadotropin suppression (secondary hypogonadism predominates)
- Direct testicular damage with evidence of orchitis in autopsy specimens
- SARS-CoV-2 detection in testicular tissue in severe cases
- Inflammation-mediated cholesterol reduction impairing androgen synthesis 4
While some cases show elevated LH/FSH with low testosterone (suggesting primary testicular failure), the majority demonstrate central suppression 1, 3.
Clinical Significance and Severity Correlation
Lower testosterone levels at hospital admission independently predict:
- 18-fold higher mortality risk in men with testosterone <100 ng/dL versus >230 ng/dL 4
- Increased ICU admission rates 2, 3
- Higher inflammatory markers (CRP, IL-6) 4
- More severe disease progression 2
Older age and lower baseline testosterone are independent predictors of symptomatic COVID-19 infection 5.
Recovery Timeline
The hormonal imbalance is generally temporary 1, 5:
- Significant testosterone recovery occurs by 3 months post-infection in symptomatic patients
- Asymptomatic patients show recovery patterns by 3 months
- LH:testosterone ratios normalize alongside testosterone recovery
- No robust long-term follow-up data exist beyond 6 months 1
Clinical Management Algorithm
Based on 2022 Endocrine Practice guidelines 1:
During acute infection:
- Document testosterone, LH, FSH only if hypogonadism is biochemically suspected
At 3 months post-discharge:
- Test testosterone, LH, FSH only if hypogonadism was documented during acute phase
- Test all men with new-onset erectile dysfunction or loss of libido, regardless of acute phase status
- Consider psychiatry referral for psychogenic erectile dysfunction if hormones are normal
If hypogonadism persists at follow-up:
- Low testosterone + low/normal LH/FSH → evaluate for hypopituitarism and check prolactin 1
- Low testosterone + elevated LH/FSH → suspect primary testicular failure 1
- Perform semen analysis only in reproductive-age men desiring children 1
Do NOT routinely test:
- Men with normal gonadal function during acute phase 1
- Men whose gonadal function was never assessed during acute phase 1
- Asymptomatic men without sexual complaints 1
Important Caveats
- Testosterone replacement therapy (TRT) does not increase COVID-19 risk and should not be withheld in appropriate candidates 6
- COVID-19 vaccines do not cause male infertility 1
- COVID-19 may attenuate treatment response to TRT if infection occurs during therapy 6
- Semen parameters may be affected (particularly in severe cases with azoospermia rates of 80% in ICU patients), but this typically recovers 1
The evidence unequivocally shows testosterone decreases, not increases, with COVID-19, representing a clinically significant hormonal imbalance that serves as both a risk factor for and consequence of severe disease.